Korge, Bernhard
Vanhooteghem, Olivier
Lynde, Charles W.
Machovcova, Alena
Perrussel, Marc
Lazaridou, Elisavet
Marasca, Claudio
Sarro, David Vidal
Pousa, Ines Duenas
Fierens, Frederik
Williams, Paulette
Shimizu, Saori
Heidbrede, Tanja
Warren, Richard B.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study
https://doi.org/10.1007/s13555-024-01210-3
Funding for this research was provided by:
UCB Pharma
Article History
Received: 30 April 2024
Accepted: 7 June 2024
First Online: 27 June 2024
Declarations
:
: Bernhard Korge was an advisor to, and/or received speakers’ honoraria from, and/or received grants from, and/or participated in clinical trials from Abbvie, Almirall Hermal, Amgen, Beiersdorf Dermo Medical, Biogen, Bristol Myers Sqibb, Celgene, Dr. Pfleger, Galderma, Janssen-Cilag, Leo Pharma, Lilly, Novartis, Pierre Fabre, UCB Pharma. Charles W Lynde received speaker fees and/or research grants from and/or participated in advisory boards of Abbvie, Amgen, Biogen, Eli Lilly, Janssen, Novartis, Sanofi Genzyme UCB Pharma. Alena Machovcova participated in clinical trials and/or received honoraria as an investigator from, and/or participated in advisory boards, and/or received speaker fees from AbbVie, Almirall, Amgen, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi Genzyme and UCB Pharma. Elisavet Lazaridou received speaker fees and research grants from and/or participated in advisory boards from UCB Pharma. David Vidal Sarro participated in clinical trials and/or received honoraria as a consultant and/or investigator, and/or received speaker fees from AbbVie, Almirall, Janssen, Lilly, Novartis and UCB Pharma. Ines D Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, and Tanja Heidbred are employees of UCB Pharma. Richard B Warren received consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis, and UCB Pharma; and honoraria from Astellas, DiCE, GSK, and Union. Richard B Warren is an Editor-in-Chief of<i> Dermatology and Therapy</i>. Richard Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Olivier Vanhooteghem, Marc Perrussel, and Claudio Marasca report no conflicts of interest in this work.
: CIMREAL was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines and with the Helsinki Declaration of 1975, as revised in 1983. Approval to conduct this study was obtained from the respective ethics committees of all participating centers. The patients in this manuscript have given written informed consent to the publication of their case details.